For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) N-terminal fragment, stabilized with a Pro-Gly-Pro C-terminal extension. It retains the neurotrophic and neuroprotective properties of ACTH fragments without any adrenocortical hormonal activity. Approved in Russia and Ukraine since the 1990s for stroke, optic nerve disease, and cognitive decline. Human clinical data includes a 30-patient stroke trial (Gusev et al., 1997), a 110-patient BDNF/rehabilitation study (Gusev et al., 2018), and a 24-subject placebo-controlled fMRI study in healthy volunteers (Lebedeva et al., 2018). All evidence is Russian-origin with no Western GCP replication.
Semax shares the same structural evidence limitation as its companion compound Selank: all clinical evidence originates from Russian institutions, is published primarily in Russian-language journals, and has not been replicated by independent international groups in 25+ years of market availability. No FDA, EMA, or equivalent regulatory authority outside Russia and Ukraine has reviewed the clinical data package.
What distinguishes Semax from most research peptides is that it occupies a genuine clinical position in Russian medical practice. It is on the Russian List of Vital and Essential Drugs (approved 2011), is routinely prescribed for acute ischemic stroke and chronic cerebrovascular disease, and has been used in human patients for approximately three decades. The pivotal stroke study (Gusev et al., 1997) involved 30 Semax-treated patients compared to 80 controls. A subsequent BDNF-endpoint study (Gusev et al., 2018) involved 110 post-stroke patients. A placebo-controlled fMRI study in 24 healthy subjects (Lebedeva et al., 2018) provides the most methodologically clean human data, showing measurable effects on the default mode network at 5 and 20 minutes post-intranasal administration.
None of this adds up to the evidence package required for Western regulatory approval. The Gusev 1997 study was not placebo-controlled (controls received standard care only), the outcomes were assessed by EEG and clinical scales rather than validated modern stroke endpoints, and the full text is available only in Russian. The Lebedeva 2018 fMRI study is a small mechanistic pilot (n=24), not a functional outcome study. Readers should calibrate their confidence accordingly: Semax has more human data than most research peptides, and meaningfully less than FDA-approved drugs.
Semax was developed beginning in the late 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, led by N.F. Myasoedov and colleagues. The design premise was established decades earlier: in the 1950s, researchers recognized that ACTH had behavioral and cognitive effects beyond its endocrine function. The N-terminal fragment ACTH(4-10) was identified as the minimally active sequence for these CNS effects. Systematic truncation and modification work identified ACTH(4-7) as the core cognitive-active tetrapeptide, and addition of the Pro-Gly-Pro tripeptide to the C-terminus conferred metabolic stability and extended duration of action from minutes to approximately 20 to 24 hours in animal models.
The name Semax is a Russian acronym meaning 'seven amino acids' (SEM' AminoKislot in Russian). The compound was registered in Russia and Ukraine as a pharmaceutical in the mid-1990s and was included on the Russian List of Vital and Essential Drugs in 2011, a government list of medications considered essential for the national healthcare system. It is currently manufactured and dispensed as two formulations: 0.1% nasal drops for nootropic and general cognitive indications, and 1% nasal drops for acute neuroprotective indications including stroke.
A notable context for Semax's development is the Russian space program: Semax was reportedly developed partly in response to cognitive and stress management needs of cosmonauts experiencing the effects of gravitational stress and hypoxia. Animal studies confirmed protective effects against hypoxia-induced cognitive impairment, supporting this application.
Semax's mechanism of action is incompletely understood despite decades of research. The compound appears to act through several convergent pathways rather than a single defined receptor target.
Neurotrophic factor upregulation is the most consistently documented mechanism. Dolotov et al. (2006, Journal of Neurochemistry) showed that intranasal Semax (50 mcg/kg) rapidly increases BDNF (brain-derived neurotrophic factor) mRNA and protein levels in rat hippocampus, accompanied by increased TrkB tyrosine phosphorylation. Shadrina et al. (2010, Journal of Molecular Neuroscience) extended this to NGF (nerve growth factor) and to multiple brain regions including frontal cortex and retina. This simultaneous BDNF and NGF upregulation is relatively uncommon among nootropic compounds. Agapova et al. (2007) demonstrated that these neurotrophic effects persist in ischemic cortex: in a permanent MCAO model, Semax activated transcription of BDNF, NGF, TrkA, TrkC, and NT-3 in the periinfarct region, with a time course consistent with rescue of penumbral neurons.
Melanocortin receptor interaction is the proposed but unconfirmed primary receptor mechanism. As an ACTH fragment, Semax retains structural homology to melanocortin peptides. Evidence suggests MC4 receptor interaction in the CNS, but Semax's structural modifications substantially reduce affinity for classical melanocortin receptors compared to native ACTH. The exact receptor responsible for its CNS effects has not been definitively identified.
Enkephalin degradation inhibition provides a second confirmed molecular mechanism, shared with companion compound Selank. Kost et al. (2001, Bioorganicheskaya Khimiya) demonstrated that Semax inhibits enkephalin-degrading enzymes in human serum (IC50 approximately 10 micromolar), extending the half-life of endogenous leu-enkephalin and met-enkephalin. This may contribute to both anxiolytic and analgesic dimensions of the pharmacological profile.
Monoaminergic modulation: Semax increases serotonin turnover in the hippocampus and prefrontal cortex, and modulates dopaminergic neurotransmission. In rodent studies, Semax potentiated the locomotor-stimulating effects of d-amphetamine, suggesting dopaminergic sensitization. Notably, Semax does not primarily elevate dopamine directly but appears to tune dopaminergic system responsivity.
Genome-wide transcriptional effects: Medvedeva et al. (2014, BMC Genomics) used RNA-Seq analysis in a rat tMCAO model and identified 394 differentially expressed genes (greater than 1.5-fold change) in Semax-treated versus control ischemic brain at 24 hours. Gene ontology analysis showed enrichment for immune system regulation and vascular function, suggesting broad transcriptomic neuroprotection beyond the specific neurotrophic mechanisms.
Gusev et al. (1997) examined 30 patients with acute hemispheric ischemic stroke who received Semax added to standard intensive care, compared to 80 matched controls on standard care alone. Semax-treated patients showed accelerated improvement on neurological function scales. EEG monitoring and somatosensory evoked potential mapping documented faster normalization of electrophysiological parameters. The study established Semax's role in Russian stroke treatment protocols and contributed to its regulatory approval.
Gusev et al. (2018) provided the strongest published human evidence for Semax's mechanism of action in clinical use. In 110 post-stroke patients, Semax (6,000 mcg/day, two 10-day courses) significantly increased plasma BDNF levels compared to patients not receiving Semax, and these elevated BDNF levels persisted throughout the study period. Elevated BDNF correlated positively with improved Barthel index scores (functional independence) and motor performance on the Medical Research Council scale. The semax-plus-early-rehabilitation combination produced the best functional outcomes. The study also found a positive correlation between BDNF plasma levels and Barthel score across all groups, with early rehabilitation modifying this correlation.
These findings provide in-human mechanistic validation of the BDNF-upregulation pathway as a relevant clinical mechanism, not just a preclinical observation.
The strongest human clinical evidence for Semax. The Gusev 2018 study is well-structured with 110 patients and validates the BDNF mechanism in human stroke patients. However, it is an observational design with subgroup comparison rather than a placebo-controlled RCT. The 1997 study lacked placebo controls. No independent validation outside Russia exists. For clinical confidence, these studies provide a mechanistic and signals framework; what is missing is a rigorous placebo-controlled international trial.
The Alzheimer's Drug Discovery Foundation (ADDF) Cognitive Vitality program, which provides independent evidence-based assessments of cognitive compounds, reviewed the available Semax literature and concluded that while Semax may benefit stroke patients based on Russian data, the published literature of well-conducted studies is lacking. This assessment from an independent Western organization reflects the same structural limitation identified for Selank.
All published Semax human clinical studies originate from Russian institutions, primarily associated with the same group (Myasoedov, Gusev, and colleagues) that developed the compound. No ClinicalTrials.gov registrations exist for any Semax clinical study. No English-language primary publication of the pivotal 1997 stroke study has been made. The compound has been available for approximately 25 years with no published independent international clinical replication.
None of the human clinical trials for Semax include placebo controls in the conventional sense: the Gusev 1997 study compared Semax-plus-standard-care to standard-care-alone, and the Gusev 2018 study used subgroup comparisons within a non-randomized observational design. This means the absolute drug effect cannot be separated from natural recovery and differential treatment intensity.
The Russian regulatory approval represents genuine review of clinical data by the Ministry of Health. But the evidence basis for that approval was never subjected to the independent scrutiny of FDA, EMA, or equivalent authority review.
This is the most important framing context for the entire Semax profile. The evidence is meaningfully better than animal-only compounds. It is meaningfully less than compounds with Western regulatory approval. The ADDF's independent assessment, after reviewing all accessible literature, is that well-conducted studies are lacking. That honest verdict belongs front-and-center alongside the Russian clinical data.
Lebedeva et al. (2018) is the most methodologically rigorous published Semax human study with a placebo control. In 24 healthy middle-aged volunteers, single intranasal 1% Semax administration produced a significantly greater volume of the default mode network rostral subcomponent (specifically the medial frontal cortex) at both 5 and 20 minutes post-administration compared to placebo. The medial frontal cortex region is involved in information processing, episodic memory retrieval, and self-referential cognition. This is a direct brain imaging demonstration of Semax CNS activity in humans at a dose relevant to nootropic use.
Panikratova et al. (2020) extended this to functional connectivity in 52 subjects, finding Semax-specific changes in amygdala-temporal cortex connectivity distinct from Selank effects, providing further imaging evidence of differential CNS activity.
The earlier Kaplan et al. study (accessible primarily through Russian review citations) reportedly showed improved attention and short-term memory at 250 to 1000 mcg/kg in healthy volunteers, with EEG changes consistent with other neuroprotective drugs. This is the basis for the widely cited nootropic application but the primary data remains largely inaccessible in English.
Lebedeva 2018 is genuinely important: it is a small placebo-controlled fMRI study that demonstrates measurable brain network effects in healthy humans at a relevant dose. This is more direct human CNS evidence than most research peptides can claim. The limitation is that an fMRI connectivity change does not translate directly to a cognitive performance outcome, and the sample (n=24, n=14 Semax) is small. The Kaplan volunteer cognitive data, while widely cited, is difficult to fully assess from the English-language literature.
Semax is approved in Russia for optic nerve atrophy and related conditions, representing one of its four core approved indications alongside stroke, dyscirculatory encephalopathy, and cognitive decline. Russian ophthalmological practice uses 1% intranasal Semax in courses for visual deterioration associated with optic nerve damage.
The mechanistic basis for optic nerve protection is supported by Dolotov et al. (2006), who demonstrated that Semax rapidly induces BDNF and NGF expression in rat retina in addition to hippocampus and frontal cortex. Both neurotrophins are important for retinal ganglion cell survival and optic nerve integrity. The compound's neurotrophic effects are therefore not limited to the brain proper but extend to retinal and optic nerve tissue.
The clinical evidence base for optic nerve indications is the most limited of Semax's approved uses: primary publications are in Russian ophthalmology journals from the 1990s to 2000s, without accessible English-language primary data.
Optic nerve atrophy represents an approved indication in Russia with a coherent biological mechanism (BDNF/NGF upregulation in retina). The human clinical evidence is the weakest of Semax's approved indications from an English-language accessibility standpoint. The neurotrophic mechanism in retinal tissue is well-established preclinically. Independent validation does not exist.
A study in 27 patients with motor neuron disease (MND, also known as ALS) administered intranasal Semax at a high dose of 12 mg/day in two 10-day courses. The study found that Semax did not affect disease progression, muscle activity on EMG assessment, or quality of life scores. This is a null result in a condition where Semax's neurotrophic properties might theoretically confer benefit.
The failure to show benefit in MND is clinically important for two reasons. First, it demonstrates that Semax's BDNF-upregulating properties are not universally disease-modifying across neurodegenerative conditions. Second, it provides a data point on high-dose safety (12 mg/day intranasally over short courses) in a clinical population, with no reported serious adverse events, suggesting tolerability even at doses substantially above nootropic-use levels.
The MND result should not be over-interpreted: this is a single small study in a disease with very high heterogeneity and no established standard of care for disease modification. However, it is a negative result that belongs in an honest evidence summary.
A null result in 27 MND patients at 12 mg/day. BDNF upregulation does not translate to benefit in MND/ALS, at least over the study duration. Important for calibrating expectations about Semax's scope of action. Also provides useful high-dose safety data. Single small study, Russian literature.
Russian-approved for stroke and cognitive disorders. Sub-Q dosing used in research community.
Semax has more accessible human dosing data than most research peptides outside approved drugs, derived from Russian clinical use and published studies. The 0.1% formulation (nootropic standard) delivers approximately 75 mcg per drop; 2 drops per nostril twice daily yields approximately 600 mcg/day. The 1% formulation (stroke/neuroprotective) delivers approximately 750 mcg per drop at the same volume; 2 drops per nostril three times daily yields approximately 9,000 mcg/day. The subcutaneous route is used by the research community but was not formally studied in the human clinical trials that supported Russian approval. N-Acetyl Semax Amidate is a chemically modified analog with no independent clinical trial data. Blood glucose monitoring is advisable in diabetic users based on the reported incidence of mild hyperglycemia (approximately 7.4%) in one Russian review. Semax modulates serotonergic and dopaminergic systems; caution is warranted with concurrent serotonergic or dopaminergic drugs.
Semax and Selank (profile #49) are sister compounds from the same Russian Institute of Molecular Genetics program, with nearly identical evidence structures: Russian regulatory approval, human clinical data from developers, and no Western GCP replication. The pharmacological split is clear: Semax is pro-focus and neuroprotective via BDNF/monoamine mechanisms; Selank is anxiolytic via allosteric GABAergic modulation. Among nootropic compounds in this series, Semax has more mechanistically specific and translatable human data than Dihexa (retracted foundational paper), Epithalon (minimal GCP-quality human data), or PE 22-28 (zero human administration data). Cerebrolysin (profile #14) has stronger evidence for stroke recovery (Phase 3 RCT data, Cochrane reviews) but is a porcine-derived multi-peptide mixture rather than a defined compound. FGL (profile #39) has one Phase 1 PK study in humans but no efficacy data whatsoever.
Semax has 25+ years of prescription use in Russia and Ukraine, representing the most extensive real-world human safety dataset of any research peptide outside formally FDA/EMA-approved compounds. The safety profile from this experience is favorable.
In clinical studies, Semax was well tolerated at doses from the standard 0.1% formulation (approximately 300 to 600 mcg/day) through stroke dosing (6,000 to 12,000 mcg/day). No serious adverse events attributable to Semax have been published from either clinical trials or post-marketing surveillance in Russia.
Reported adverse effects are limited and mild. The most common is transient nasal mucosal irritation from the intranasal formulation, analogous to other intranasal peptide preparations. Kolomin et al. (2013) noted that an increase in blood glucose levels was observed in diabetic patients (in approximately 7.4% of patients in that review), a finding that warrants monitoring in diabetic users. Some users report mild anxiety or increased alertness at higher doses, which appears to be related to the serotonergic and dopaminergic stimulation.
Semax lacks adrenocortical hormonal activity: it does not stimulate cortisol release from the adrenal glands. This is a critical pharmacological safety distinction from native ACTH, which would cause significant endocrine side effects at comparable doses.
Important safety caveats: the Russian safety database does not meet ICH E1 standards for long-term safety assessment. One animal study (high dose) noted a pro-oxidant effect at very high concentrations; lower doses showed antioxidant effects. The clinical significance is unknown. Semax modulates monoaminergic systems and caution is warranted with concurrent use of SSRIs, MAOIs, or other serotonergic or dopaminergic agents. No reproductive safety data is available; Semax should not be used in pregnancy or breastfeeding.
Semax is the neuroprotection and nootropic counterpart to Selank's anxiolytic focus. Both emerged from the same Russian peptide program, share the Pro-Gly-Pro stabilization design, and face the same structural evidence limitation: Russian-only clinical data from the compound's developers, without placebo controls or international replication. Semax has been in clinical use for approximately 25 years, is on Russia's List of Vital and Essential Drugs, and has published human data from stroke patients (n=30 and n=110) and healthy volunteers (n=24, placebo-controlled fMRI).
The ADDF independent assessment -- that well-conducted studies are lacking despite market availability -- is the honest bottom line. Semax's human evidence is meaningfully stronger than compounds with zero clinical data. It is meaningfully weaker than what FDA or EMA approval would require.
The mechanistic story for Semax is arguably the most coherent of any nootropic research peptide: BDNF and NGF upregulation in brain and retina, confirmed in both rodents and post-stroke human plasma data; broader genome-wide transcriptional effects in ischemic brain tissue; modulation of serotonergic and dopaminergic systems without direct adrenocortical stimulation. The fMRI evidence that single intranasal doses produce measurable default mode network changes in healthy humans provides direct translational confirmation at relevant doses.
For researchers: Semax is one of the most mechanistically characterized nootropic peptides available, with genuine human clinical data from its approved use. The absence of a well-designed placebo-controlled Western trial after 25+ years of market availability is a puzzling gap. The null MND result is important context: BDNF upregulation is not a universal clinical benefit across neurological conditions. Blood glucose monitoring is warranted in diabetic users.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use